{"pageContent": "Background/aim: Degarelix has been widely used for prostate cancer; however, injection site reactions (ISRs) can be a clinical issue. We assessed differences in ISR intensity and patient quality of life (QOL) between degarelix 80 mg and 480 mg, a three-month formulation launched in 2020 in Japan.", "metaData": {"source": "Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells\nhttps://pubmed.ncbi.nlm.nih.gov/12080185/"}}